GlobeNewswire

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
30/10/2026
JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the [...]
Nathan Fielder Meets Ryan ElHosseiny: The Science Behind “The Strip Club” and “Who’s on First” in You Can See Everything
30/10/2026
MIAMI, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Ryan “Egypt” ElHosseiny, brings over 20 years of laboratory diagnostics experience to Nathan Fielder's You Can See Everything . His new short film, Lab Stripping , reveals the [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/10/2026
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab
30/10/2026
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available for efficient cath lab workflows At TCT 2026, Philips will showcase its broader full picture [...]
SRX Global Provides Update on Balance Sheet and Share Buyback
30/10/2026
NORTH PALM BEACH, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in [...]
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
30/10/2026
WOODCLIFF LAKE, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “ [...]
TME Pharma Publishes Its Semi Annual Results and Half-Year Report
30/10/2026
TME Pharma Publishes Its Semi Annual Results and Half-Year Report Berlin, Germany , October 30, 2026, 18:00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer [...]
TME Pharma publie ses résultats semestriels et son rapport semestriel
30/10/2026
TME Pharma publie ses résultats semestriels et son rapport semestriel Berlin, Allemagne, le 30 octobre 2026, 18 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie disposant d' [...]
Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace
30/10/2026
An Equipment Innovator’s Interest in Kraig’s High Tech Fibers Indicates Potential Applications for Lightweight and/or Tough Materials, and Possibly Elevate Project Atlas DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( www. [...]
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
30/10/2026
500 Patients, 30 Hospitals, 3 Countries is Part of the Setup DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest whizbang trends often dominate investor attention, NeOnc [...]
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
30/10/2026
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary [...]
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
30/10/2026
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss [...]
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
30/10/2026
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax [...]
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
30/10/2026
PRESS RELEASE, October 30, 2026 – 08:00 CDT Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026 ITASCA, IL, US – October 30, 2026. Today, Biocartis , an innovative [...]
Femasys Appoints John Moorhead to Board of Directors
30/10/2026
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the [...]
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
30/10/2026
Redesigned site brings together information on BGLC’s operating businesses, healthcare initiatives and public disclosures KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC [...]
Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association
30/10/2026
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders [...]
Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene Therapy for Usher Syndrome Type 1B
30/10/2026
Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachment Six-month GLP toxicology study establishes [...]
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
30/10/2026
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum